ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,584.54
      -0.88%
      US Tech 100
      19,676.00
      -2.20%
      Dow Jones
      39,753.75
      0.08%
      Brent Oil
      85.06
      0.01%
      Bitcoin
      57,373.05
      -0.66%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. AMEX
      6. Can Fite BioPharma Ltd (CANF)

      7. Can Fite BioPharma Ltd (CANF) News

      CANF

      Can Fite BioPharma (CANF)

      Can Fite BioPharma Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:AMEX:CANF
      DateTimeSourceHeadlineSymbolCompany
      12:21PMiHub NewswireFeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
      05/02/20237:09AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      05/02/20237:00AMBusiness WireInhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite ScientistsAMEX:CANFCan Fite BioPharma Ltd
      04/24/20237:10AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      04/24/20237:00AMBusiness WireCan-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward CommercializationAMEX:CANFCan Fite BioPharma Ltd
      04/21/20234:16PMEdgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)AMEX:CANFCan Fite BioPharma Ltd
      04/21/20234:16PMEdgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)AMEX:CANFCan Fite BioPharma Ltd
      04/10/20237:07AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      04/10/20237:00AMBusiness WireCan-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis TreatmentAMEX:CANFCan Fite BioPharma Ltd
      03/31/20234:32PMEdgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)AMEX:CANFCan Fite BioPharma Ltd
      03/30/20237:58AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      03/30/20237:55AMEdgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)AMEX:CANFCan Fite BioPharma Ltd
      03/30/20237:15AMBusiness WireCan-Fite Reports 2022 Financial Results & Provides Clinical UpdateAMEX:CANFCan Fite BioPharma Ltd
      03/16/20237:00AMBusiness WireCan-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and NamodenosonAMEX:CANFCan Fite BioPharma Ltd
      03/13/20237:00AMBusiness WireCan-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use SettingAMEX:CANFCan Fite BioPharma Ltd
      02/22/20234:16PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      02/14/20237:14AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      02/14/20237:00AMBusiness WireNovel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for PlaceboAMEX:CANFCan Fite BioPharma Ltd
      02/13/20236:08AMEdgar (US Regulatory)Notice of Effectiveness (effect)AMEX:CANFCan Fite BioPharma Ltd
      02/10/20234:54PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)AMEX:CANFCan Fite BioPharma Ltd
      02/10/20234:19PMEdgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)AMEX:CANFCan Fite BioPharma Ltd
      01/24/20237:12AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      01/24/20237:00AMBusiness WireCan-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been FiledAMEX:CANFCan Fite BioPharma Ltd
      01/13/20234:16PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)AMEX:CANFCan Fite BioPharma Ltd
      01/13/202312:39PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)AMEX:CANFCan Fite BioPharma Ltd
      01/13/202311:48AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      01/11/20239:04AMBusiness WireCan-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private PlacementAMEX:CANFCan Fite BioPharma Ltd
      01/10/20237:06AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      01/10/20237:00AMBusiness WireCan-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to FollowAMEX:CANFCan Fite BioPharma Ltd
      12/30/20224:41PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
       Showing the most relevant articles for your search:AMEX:CANF

      Your Recent History

      BIT
      F05979
      Vontobel Financial Produ...
      Delayed Upgrade Clock